Ignite Creation Date:
2025-12-24 @ 4:21 PM
Ignite Modification Date:
2026-01-10 @ 2:32 PM
Study NCT ID:
NCT06202066
Status:
SUSPENDED
Last Update Posted:
2025-12-19
First Post:
2023-12-29
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Temozolomide and Survivin Long Peptide Vaccine (SurVaxM) for the Treatment of Patients With Progressing Metastatic Neuroendocrine Carcinomas
Sponsor:
Roswell Park Cancer Institute
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-02-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2027-10-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-10-15
Completion Date Type:
ESTIMATED
First Submit Date:
2023-12-29
First Submit QC Date:
None
Study First Post Date:
2024-01-11
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-12-17
Last Update Post Date:
2025-12-19
Last Update Post Date Type:
ESTIMATED